| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Research (A.M.D., D.D., E.C.), Saint Francis Hospital and Medical Center, Hartford, Connecticut 06105; and The University of Connecticut School of Medicine (A.M.D., E.C.), Farmington, Connecticut 06030
Address all correspondence and requests for reprints to: Anne M. Delany, Ph.D., Department of Research, Saint Francis Hospital and Medical Center, 114 Woodland Street, Hartford, Connecticut 06105-1299. E-Mail: adelany@stfranciscare.org.
Glucocorticoids have profound effects on bone formation,
decreasing IGF I transcription in osteoblasts, but the mechanisms
involved are poorly understood. We previously showed that the bp +34 to
+192 region of the rat IGF I exon 1 promoter was responsible for
repression of IGF I transcription by cortisol in cultures of
osteoblasts from fetal rat calvariae (Ob cells). Here, site-directed
mutagenesis was used to show that a binding site for members of the
CAAT/enhancer binding protein family of transcription factors,
within the +132 to +158 region of the promoter, mediates this
glucocorticoid effect. EMSAs demonstrated that cortisol increased
binding of osteoblast nuclear proteins to the +132 to +158 region of
the IGF I promoter. Supershift assays showed that CAAT/enhancer binding
protein
, ß, and
interact with this sequence, and binding of
CAAT/enhancer binding protein
, in particular, was increased in the
presence of cortisol. Northern blot analysis showed that CAAT/enhancer
binding protein
and ß transcripts were increased by cortisol in
Ob cells. Further, cortisol increased the transcription of these genes
and increased the stability of CAAT/enhancer binding protein
mRNA.
In conclusion, cortisol represses IGF I transcription in osteoblasts,
and CAAT/enhancer binding proteins appear to play a role in this
effect.
This article has been cited by other articles:
![]() |
A. Giustina, G. Mazziotti, and E. Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton Endocr. Rev., August 1, 2008; 29(5): 535 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wu, W. Zhao, J. Zhao, J. Pan, Q. Wu, Y. Zhang, W. A. Bauman, and C. P. Cardozo Identification of Androgen Response Elements in the Insulin-Like Growth Factor I Upstream Promoter Endocrinology, June 1, 2007; 148(6): 2984 - 2993. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-S. Wang, C.-L. Lin, Y.-J. Chen, C.-J. Wang, K. D. Yang, Y.-T. Huang, Y.-C. Sun, and H.-C. Huang Secreted Frizzled-Related Protein 1 Modulates Glucocorticoid Attenuation of Osteogenic Activities and Bone Mass Endocrinology, May 1, 2005; 146(5): 2415 - 2423. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-F. Iu, H. Kaji, H. Sowa, J. Naito, T. Sugimoto, and K. Chihara Dexamethasone suppresses Smad3 pathway in osteoblastic cells J. Endocrinol., April 1, 2005; 185(1): 131 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Eijken, M. Hewison, M. S. Cooper, F. H. de Jong, H. Chiba, P. M. Stewart, A. G. Uitterlinden, H. A. P. Pols, and J. P. T. M. van Leeuwen 11{beta}-Hydroxysteroid Dehydrogenase Expression and Glucocorticoid Synthesis Are Directed by a Molecular Switch during Osteoblast Differentiation Mol. Endocrinol., March 1, 2005; 19(3): 621 - 631. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Dhawan, X. Peng, A. L. M. Sutton, P. N. MacDonald, C. M. Croniger, C. Trautwein, M. Centrella, T. L. McCarthy, and S. Christakos Functional Cooperation between CCAAT/Enhancer-Binding Proteins and the Vitamin D Receptor in Regulation of 25-Hydroxyvitamin D3 24-Hydroxylase Mol. Cell. Biol., January 1, 2005; 25(1): 472 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Koutsilieris, C. S. Mitsiades, J. Bogdanos, T. Dimopoulos, D. Karamanolakis, C. Milathianakis, and A. Tsintavis Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases Clin. Cancer Res., July 1, 2004; 10(13): 4398 - 4405. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Pereira, A. M. Delany, and E. Canalis CCAAT/Enhancer Binding Protein Homologous Protein (DDIT3) Induces Osteoblastic Cell Differentiation Endocrinology, April 1, 2004; 145(4): 1952 - 1960. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sciaudone, E. Gazzerro, L. Priest, A. M. Delany, and E. Canalis Notch 1 Impairs Osteoblastic Cell Differentiation Endocrinology, December 1, 2003; 144(12): 5631 - 5639. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Delany, I. Kalajzic, A. D. Bradshaw, E. H. Sage, and E. Canalis Osteonectin-Null Mutation Compromises Osteoblast Formation, Maturation, and Survival Endocrinology, June 1, 2003; 144(6): 2588 - 2596. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Canalis, A. N. Economides, and E. Gazzerro Bone Morphogenetic Proteins, Their Antagonists, and the Skeleton Endocr. Rev., April 1, 2003; 24(2): 218 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Canalis and A. Giustina Glucocorticoid-Induced Osteoporosis: Summary of a Workshop J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5681 - 5685. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |